Evidence on real-world persistence of β3-adrenoceptor agonists in patients aged ≥ 80 years with overactive bladder (OAB) is limited. We evaluated vibegron persistence and examined whether polypharmacy, anticholinergic cognitive burden (ACB), and prior anticholinergic exposure were associated with time to treatment discontinuation.
Keywords: Overactive bladder, Persistence, Polypharmacy, Propensity score matching, Super-elderly, Vibegron
World journal of urology
Journal Article
English
41874710
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.